Browsing Tag
Nectin-4
2 posts
Corbus Pharmaceuticals (NASDAQ: CRBP) lands FDA clearance for TEMPO-1 as CRB-701 enters Phase 3
CRB-701 delivered a 42.9% ORR in 2L OPSCC. Corbus Pharmaceuticals must now reproduce it in a 250-patient TEMPO-1 trial that starts enrolling in September.
How CLD-401 and RedTail may redefine tumor-localized immune activation in solid tumors
Can RedTail and CLD-401 change solid tumor immunotherapy? Read why Calidi Biotherapeutics, Inc.’s next milestones could reshape the CLDI story.